Bioperfectus Mass Distribution of Rapid COVID-19 Tests in Israel Begins

Company news

The demand for rapid tests is expected to go up after the government announced that the mandatory quarantine period for Israelis infected with COVID-19 would be shortened from a week to five days on January 17th, 2022. According to Israel’s Health Ministry, a negative home antigen test is also required before ending isolation.


Prime Minister Naftali Bennett said a spike in infections due to the Omicron variant of the coronavirus and the number of people in isolation has become a burden on the Israeli economy.


With Omicron spreading the globe wide, the burden of the COVID-19 pandemic seems to overshadow the economy and growth.



We Bioperfectus have recently received the feedback of our SARS-CoV-2 antigen rapid test from Israel that our Novel Corona Virus (SARS-CoV-2) Ag Rapid Test showed reliability when detecting Omicron variant. With market access approval and quality assurance in the local Israel market, Bioperfectus now begins to distribute our products through the tender relationship of Israel’s Ministry of Health.



Bioperfectus rapid antigen tests shine in the global market with their versatile features, easy to use, multiple market access,  multilingual packaging, and fast delivery. 



Contact us today to get more information about our product and service now!

Email:; marketing_global@bioperfectus .com

Tel: 86-021 54847326


Bioperfectus Supports Cholera Elimination

SHANGHAI, CHINA, December 5, 2022—Jiangsu Bioperfectus Technologies Co., Ltd. (hereinafter referred to as “Bioperfectus”) is pleased to launch Vibrio Cholerae Real Time PCR Kits for human diagnosis and early warning surveillance.


Client Story: A Race Against Time

Through a critical assessment of clinical evaluation and data validation, Bioperfetus successfully passed the Israeli ministry of health inspection. Bioperfetus was the only Chinese company on the procurement list and was asked to provide one million antigen rapid test kits for the Israeli ministry of health.


Bioperfectus Granted MDA Approval in Malaysia for Nucleic Acid Extraction Systems

SHANGHAI, CHINA, November 14, 2022—Jiangsu Bioperfectus Technologies Co., Ltd. (hereinafter referred to as “Bioperfectus”), a leading global company in the molecular diagnostics market, today announced receipt of MDA (Medical Device Authority) approval in Malaysia for Nucleic Acid Extraction Systems, including Nucleic Acid SSNP-2000B, SSNP-3000A, SSNP-9600A, SMPE-960 and Extraction Rapid Kit (Magnetic Bead Method).